ArticleEmergency medicine Australasia : EMA2025
Balancing Act: Digoxin Antidote Supply and Demand in New South Wales, Australia.
Article in Emergency medicine Australasia : EMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Balancing Act: Digoxin Antidote Supply and Demand in New South Wales, Australia.Emergency medicine Australasia : EMA · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to evaluate the supply and demand of digoxin antibody (Digoxin-Fab) in New South Wales (NSW) hospitals before and after the updated Therapeutic Guidelines (TG) for digoxin poisoning introduced in August 2020. We also aim to propose standardised stocking recommendations for NSW public hospitals.
methodsThis retrospective multicentre study analysed data from the New South Wales Poisons Information Centre (NSWPIC) to assess Digoxin-Fab demand, and from the Life Saving Drugs Register (LSDR) to assess supply in NSW hospitals between January 2017 and December 2022.
resultsA total of 166 cases of digoxin poisoning were identified in NSW: 149 chronic cases across 34 hospitals and 17 acute cases across 14 hospitals. Following the updated TG, the proportion of chronic cases where clinical toxicologists advised Digoxin-Fab (either 'immediately' or 'if clinically indicated') decreased from 39.5% to 31.7% (Risk Difference [RD]: 0.08, 95% Confidence Interval [CI]: -0.09 to 0.23, p = 0.39). For acute cases, recommendations decreased from 75% to 60% (RD: 0.15, CI: -0.31 to 0.62, p = 0.60). LSDR data showed NSW hospitals stocked 238 vials in 2018 and 246 in 2020, with uneven distribution. During the study period, two chronic cases and one acute case lacked Digoxin-Fab at the treating hospital when advised.
conclusionsWith few exceptions, Digoxin-Fab supply in NSW hospitals exceeds demand. Based on usage patterns and guideline updates, a more cost-effective and standardised stocking approach is recommended for NSW hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.